Related references
Note: Only part of the references are listed.Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
A. T. Layton et al.
ACTA PHYSIOLOGICA (2018)
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease
Menno Pruijm et al.
KIDNEY INTERNATIONAL (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism
Anita T. Layton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Lennart Tonneijck et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Selective tubular activation of hypoxia-inducible factor-2α has dual effects on renal fibrosis
Kyoung Hye Kong et al.
SCIENTIFIC REPORTS (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Girish N. Nadkarni et al.
DIABETES CARE (2017)
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Hongyu Qiu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Sergei Petrykiv et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis
K. Melissa Hallow et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
The effect of dapagliflozin on renal function in patients with type 2 diabetes
Donald Elliott Kohan et al.
JOURNAL OF NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Yoon-Kyung Chang et al.
PLOS ONE (2016)
Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron
Anita T. Layton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
Renal effects of canagliflozin in type 2 diabetes mellitus
Vlado Perkovic et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
Kamlesh Khunti et al.
DIABETES CARE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
Julie O'Neill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition
Anita T. Layton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
Timo Rieg et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension
Peter Hansell et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose-Absorption and Glucose-Dependent Incretin Secretion
Valentin Gorboulev et al.
DIABETES (2012)
The proximal tubule in the pathophysiology of the diabetic kidney
Volker Vallon
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
COMPREHENSIVE PHYSIOLOGY (2011)
Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis
Kuniko Kimura et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Debra F. Higgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type IIFN signaling following B7 ligation
B Baban et al.
INTERNATIONAL IMMUNOLOGY (2005)
Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes
SC Thomson et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
